These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 34302813

  • 1. Adenosine-to-inosine Alu RNA editing controls the stability of the pro-inflammatory long noncoding RNA NEAT1 in atherosclerotic cardiovascular disease.
    Vlachogiannis NI, Sachse M, Georgiopoulos G, Zormpas E, Bampatsias D, Delialis D, Bonini F, Galyfos G, Sigala F, Stamatelopoulos K, Gatsiou A, Stellos K.
    J Mol Cell Cardiol; 2021 Nov; 160():111-120. PubMed ID: 34302813
    [Abstract] [Full Text] [Related]

  • 2. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation.
    Stellos K, Gatsiou A, Stamatelopoulos K, Perisic Matic L, John D, Lunella FF, Jaé N, Rossbach O, Amrhein C, Sigala F, Boon RA, Fürtig B, Manavski Y, You X, Uchida S, Keller T, Boeckel JN, Franco-Cereceda A, Maegdefessel L, Chen W, Schwalbe H, Bindereif A, Eriksson P, Hedin U, Zeiher AM, Dimmeler S.
    Nat Med; 2016 Oct; 22(10):1140-1150. PubMed ID: 27595325
    [Abstract] [Full Text] [Related]

  • 3. Alu sequences in undifferentiated human embryonic stem cells display high levels of A-to-I RNA editing.
    Osenberg S, Paz Yaacov N, Safran M, Moshkovitz S, Shtrichman R, Sherf O, Jacob-Hirsch J, Keshet G, Amariglio N, Itskovitz-Eldor J, Rechavi G.
    PLoS One; 2010 Jun 21; 5(6):e11173. PubMed ID: 20574523
    [Abstract] [Full Text] [Related]

  • 4. Adenosine-to-inosine RNA editing contributes to type I interferon responses in systemic sclerosis.
    Vlachogiannis NI, Tual-Chalot S, Zormpas E, Bonini F, Ntouros PA, Pappa M, Bournia VK, Tektonidou MG, Souliotis VL, Mavragani CP, Stamatelopoulos K, Gatsiou A, Sfikakis PP, Stellos K.
    J Autoimmun; 2021 Dec 21; 125():102755. PubMed ID: 34857436
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Altered A-to-I RNA editing in human embryogenesis.
    Shtrichman R, Germanguz I, Mandel R, Ziskind A, Nahor I, Safran M, Osenberg S, Sherf O, Rechavi G, Itskovitz-Eldor J.
    PLoS One; 2012 Dec 21; 7(7):e41576. PubMed ID: 22859999
    [Abstract] [Full Text] [Related]

  • 7. A survey on cellular RNA editing activity in response to Candida albicans infections.
    Huang Y, Cao Y, Li J, Liu Y, Zhong W, Li X, Chen C, Hao P.
    BMC Genomics; 2018 Jan 19; 19(Suppl 1):43. PubMed ID: 29363428
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inosine cyanoethylation identifies A-to-I RNA editing sites in the human transcriptome.
    Sakurai M, Yano T, Kawabata H, Ueda H, Suzuki T.
    Nat Chem Biol; 2010 Oct 19; 6(10):733-40. PubMed ID: 20835228
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. RNA editing enzyme ADAR1 controls miR-381-3p-mediated expression of multidrug resistance protein MRP4 via regulation of circRNA in human renal cells.
    Omata Y, Okawa M, Haraguchi M, Tsuruta A, Matsunaga N, Koyanagi S, Ohdo S.
    J Biol Chem; 2022 Aug 19; 298(8):102184. PubMed ID: 35753353
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. RNA editing underlies genetic risk of common inflammatory diseases.
    Li Q, Gloudemans MJ, Geisinger JM, Fan B, Aguet F, Sun T, Ramaswami G, Li YI, Ma JB, Pritchard JK, Montgomery SB, Li JB.
    Nature; 2022 Aug 19; 608(7923):569-577. PubMed ID: 35922514
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
    Ganem NS, Ben-Asher N, Lamm AT.
    Drug Resist Updat; 2017 May 19; 32():16-22. PubMed ID: 29145975
    [Abstract] [Full Text] [Related]

  • 18. NEAT1/miR-140-3p/MAPK1 mediates the viability and survival of coronary endothelial cells and affects coronary atherosclerotic heart disease.
    Zhang H, Ji N, Gong X, Ni S, Wang Y.
    Acta Biochim Biophys Sin (Shanghai); 2020 Sep 08; 52(9):967-974. PubMed ID: 32844995
    [Abstract] [Full Text] [Related]

  • 19. ADAR1 prevents ZBP1-dependent PANoptosis via A-to-I RNA editing in developmental sevoflurane neurotoxicity.
    Yang H, Xu S, Hong X, Liu Y, Qian S, Lou Y, Wang W.
    Cell Biol Toxicol; 2024 Jul 25; 40(1):57. PubMed ID: 39060787
    [Abstract] [Full Text] [Related]

  • 20. Vaccinia virus E3L interferon resistance protein inhibits the interferon-induced adenosine deaminase A-to-I editing activity.
    Liu Y, Wolff KC, Jacobs BL, Samuel CE.
    Virology; 2001 Oct 25; 289(2):378-87. PubMed ID: 11689059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.